Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.
复制标题
基于依法韦仑的治疗方案，用于治疗前具有一系列治疗前 HIV-1 RNA 水平和 CD4 细胞计数的初治患者。
DOI：
10.1086/529208
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
Gulick,RoyM
中科院分区：
文献类型：
--
作者：
Ribaudo,HeatherJ;Kuritzkes,DanielR;Lalama,ChristinaM;Schouten,JeffreyT;Schackman,BruceR;Acosta,EdwardP;Gulick,RoyM
2种核苷逆转录酶抑制剂（NRTI）和依法韦仑在病毒载量（VL）较高或CD4细胞计数较低的患者中的效力仍不确定。在随机分配至接受2或3种NRTI联合依法韦仑治疗组的初治患者中，评价病毒学失败和与治疗前VL和CD4计数相关的CD4计数变化。3年以上，根据治疗前VL或CD4计数分类的亚组之间病毒学失败的风险无显著差异。除治疗前VL较高的患者外，未观察到亚组间CD4计数变化的显著差异。各亚组之间的治疗反应无显著差异。这些结果证明了含依法韦仑方案在一系列治疗前VL和CD4计数中的效力。试验registrationClinicalTrials.gov标识符：NCT 00013520
The potency of 2 nucleoside reverse transcriptase inhibitors (NRTIs) and efavirenz in patients with higher viral loads (VLs) or low CD4 cell counts remains uncertain. Virologic failure and changes in CD4 count in relation to pretreatment VL and CD4 count were evaluated in treatment-naive patients randomized to treatment groups that received 2 or 3 NRTIs with efavirenz. Over 3 years, the risk of virologic failure was not significantly different among subgroups categorized according to pretreatment VL or CD4 count. No significant differences among subgroups were observed for CD4 count changes, except in patients with high pretreatment VL. There were no significant differences among subgroups with respect to treatment responses. These results demonstrate the potency of efavirenz-containing regimens across a spectrum of pretreatment VLs and CD4 countsTrials registrationClinicalTrials.gov Identifier: NCT00013520
影响因子：
6.4
作者：
Smith, CJ;Sabin, CA;Phillips, AN
通讯作者：
Phillips, AN